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A single RGD-containing sequence present within an epidermal growth factor-like repeat of the short arms of laminin is shown by peptide inhibition 
to block integrin receptors recognizing a latent cell-binding site of laminin. Based on proteolysis data it is proposed that masking occurs by folding 
of the globular domain IVa over the cell-binding site in the adjacent rod-like structures of laminin A chain. 
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1. I~RODUCTION 
Fragment P 1 generated from laminin by pepsin treat- 
ment was the first domain of the protein shown to be 
involved in cellular interactions [1,2]. Various cells 
have been found which bind fragment Pl with high af- 
finity (KD - l-4 nM) to an apparently homogenous 
class of receptors [3-51. It was later shown that this 
binding site is latent both within laminin and within a 
larger PI-related fragment produced by cleavage with 
elastase [6], The Pl fragment (about 200 kDa) com- 
prises the inner rod-like structure of the short arms of 
laminin and contains some 28 EGF-like repeats con- 
tributed by the A, Bl and B2 chains of laminin [7-91. 
Its A chain segment also possesses the only RGD (Arg- 
Gly-Asp) sequence present in mouse laminin [9]. 
Similar sequences are involved in cell binding to several 
other proteins including fibronectin, vitronectin and 
collagens [lo]. Here, we show by peptide and antibody 
inhibition and by proteolytic inactivation that the 
laminin RGD sequence very likely corresponds to the 
latent cell-binding site identified previously [6], and is 
recognized by cellular receptors of the integrin family. 
2. EXPERIMENTAL 
The mouse EHS tumor laminin-nidogen complex ill] and its large 
tryptic fragment Tl (121 were prepared as previously described. Both 
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components were cleaved in 0.1 M glycine-HCl, pH 1.9 with pepsin 
(24 h, 25”C, enzyme-substrate ratio 1:iOO) to generate fragment PI 
which was then purified on a molecular sieve fl2]. Some small pep- 
tides in the pepsin digest were bound to heparin-Sepharose (Phar- 
macia) equilibrated in 0.1 M NaCl, 0.05 M Tris-HCl, pH 7.4 and 
eluted with 0.5 M NaCl. This material was separated into 25 distinct 
peaks by reversed phase HPLC and individual peptides were iden- 
tified by Edman degradation [13]. Trypsin inactivation of PI some 
synthetic peptides was performed at 37°C in 0.2 M NH4HCOa 
(enzyme-substrate ratio 1:lOO) and the reaction was stopped by 
adding TLCK. Laminin fragment Pl was also isolated from human 
placenta [14]. Human plasma fibronectin (Behringwerke) was further 
purified on haparin-Sepharose. Synthetic peptides GRGDS (Pro- 
mega) and ROES (Peninsula) were from commercial sources. Other 
RGD-cont~~ng peptides (see fig. 1) were synthesized according to se- 
quences of mouse [P] and human fl5] laminin A chain, mouse 
laminin Bl chain 1161 and mouse nidogen (171 and kindly suppiied by 
Drs J. Knolle, S. Henke (Hoechst AG) and W. Sttiber (Behring- 
werke). They were purified by HPLC and their structure was con- 
firmed by Edman degradation. 
Cell attachment was determined in microtiter wells coated with op- 
timal substrate concentrations and adherent cells were analyzed after 
staining with Crystal violet by a calorimetric assay [18]. In the inhibi- 
tion assays cells (l-5 x Id/ml) were mixed with synthetic peptides 
(l-500 pg/ml) or various antibody dilutions and plated for 30 min at 
37°C on coated microtiter wells. Cultured cell lines are identified in 
table 1 and were those used in previous studies [5,18,19]. A mono- 
clonal rat antibody against he cr6 subunit of integrin VLA-6 [20] and 
a rabbit antiserum against human fibronectin receptor [21] were used 
for inhibition. The latter was a kind gift from Dr G. Tarone (Univer- 
sity of Torino). 
3. RESULTS AND DISCUSSION 
Examination of the adhesion of ten different cell 
lines (table 1) to laminin fragment Pl showed typical 
dose-response profiles [5,18] with 30-80% of the cells 
bound in the plateau region. Comparable attachment 
profiles were observed for fibronectin and, with two ex- 
ceptions (A37.5, SCIII), for the laminin-nidogin com- 
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Table 1 
Inhibitory capacity (ICsc = 50% inhibition) of GRGDS peptide for 
cell adhesion on laminin fragment Pl and fibronectin (Fn) 
Cell lines IC50 @g/ml) on 
Pl Fn 
HT1080, fibrosarcoma H < 10 508 
SAOS-2, osteosarcoma H <lO >500 
A375, melanoma H < 10 nt 
HBLlOO, mammary epithelia H < 10 >500 
RN22, Schwannoma R < 10 >500 
B16F10, melanoma M <lO nt 
A431, epidermoid H 100 200 
SClI, epithelial Ca H >500 nt 
SClII, epithelial Ca H 320 nt 
Rugli, glioblastoma R 50 250 
H, human; R, rat; M, mouse; Ca, carcinoma; nt, not tested 
plex. Three more teratocarcinoma cell lines (mouse F9, 
PYS-2, human Tera-2) showed strong attachment on 
fibronectin but none on fragment Pl substrates. This 
indicates the unique nature of the Pl substrate whose 
cellular recognition is not necessarily correlated to that 
of laminin and fibronection. 
Adhesion of six cell lines to fragment Pl could be 
clearly inhibited by less than 10 gg/ml(20 PM) required 
for 50% inhibition (fig.la) of synthetic GRGDS pep- 
tide (table 1) which corresponds to fibronectin cell- 
binding sequence [lo]. About 20-50 times higher pep- 
tide concentrations were needed to achieve this inhibi- 
tion for the other four cell lines. This low sensitivity for 
GRGDS inhibition was generally observed when the 
same cells were exposed to fibronectin substrates (table 
1). Peptide GRGDS (10-500 pg/ml) was completely in- 
active in inhibiting adhesion of HT1080, SAOS-2 and 
B16FlO cells to laminin or laminin-nidogen (data not 
shown). This is in agreement with the previous observa- 
tion [6] that the Pl binding site is not recognized by 
HT1080 cells in intact laminin. 
Specificity of peptide inhibition of cell adhesion to 
fragment Pl was studied by using the variant RGES 
structure which was inactive up to 5OOpg/ml for 
HT1080 (fig.la), B16FlO and SAOS-2 cells. Similar 
observations have been reported for fibronectin [22], 
collagen type VI [18] and several other cell adhesion 
substrates. Also, no inhibitory activity for HT1080 
(fig.la) and A375 cells was found for the synthetic 
CDPGYIGSR-amide peptide which was designed ac- 
cording to a B 1 chain sequence [ 161 present in fragment 
Pl. This peptide has been reported [23] to block cell 
adhesion to laminin by binding to a 68 kDa receptor. 
The RGD-containing sequence of laminin A chain [9] 
was synthesized as the 18-mer oligopeptide CQAGTF- 
ALRGDNPQGCSP-amide and used in cyclic, disul- 
fide-linked and linear, alkylated forms for inhibition. 
Both peptides were of equivalent inhibitory capacity 
when compared with GRGDS on a molar basis for cells 
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.?ig.l. Peptide inhibition of attachment of HT1080 cells (a) and of 
A431 cells (b) on a laminin fragment Pl substrate. Inhibitors used 
were GRGDS (o), RGES (0), CQAGTFALRGDNPQGCSP-amide 
corresponding to a mouse laminin A chain sequence which was used 
either in cyclic, disulfide-linked (A) or linear, S-carboxyamidated 
from (A), GDVEKRGDREEA from a human laminin A chain se- 
quence (m) SIGFRGDGQT from a mouse nidogen sequence ( q ), and 
CDPGYIGSR-amide (v) from a mouse laminin Bl chain sequence. 
highly sensitive to peptide inhibition as shown for 
HT-1080 cells (fig.la). Similar studies with cells where 
GRGDS is of low inhibitor potency against Pl also 
showed no better inhibitory activity for the authentic 
laminin peptides (fig. lb). This indicates a small binding 
sequence, unlike that indicated by observations with 
fibronectin [22,24] where larger peptides were the bet- 
ter inhibitors. It also indicates that the disulfide- 
bonded loop structure supposed to exist in the EGF-like 
repeats of laminin [25] is not important for activity. 
Another RGD sequence is found in the C-terminal 
globule of human laminin A chain [15] which is 
changed in mouse laminin [9] to AGG. A synthetic pep- 
tide corresponding to the human sequence GDVEKRG- 
DREEA was found to be of very low inhibitory potency 
for cell adhesion to fragment Pl (fig.1). A somewhat 
better activity was observed for the peptide SIGFR- 
GDGQT which corresponds to a sequence in mouse 
nidogen possibly involved in cell adhesion [ 171. This 
suggests that amino acid residues adjacent to the RGD 
sequence determine its inhibitory activity in the Pl 
adhesion assay. 
83 
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Whether the active RGD sequence as shown here is 
conserved in laminin A chain of other species or in 
isoforms [8] of the chain is so far not known. We have 
therefore used laminin fragment P 1 prepared from pep- 
sin digests of human placenta [14] in cell adhesion 
assays. Four cell lines (A375, A431, HBL-100, 
SAOS-2) showed attachment up to 60-100% of the 
plateau levels achieved with mouse laminin Pl . The at- 
tachment of A375 cells to human laminin Pl could be 
inhibited by GRGDS with a similar sensitivity when 
compared to a mouse laminin Pl substrate (data not 
shown). It indicates conservation of this particular 
RGD sequence in laminin of human and possibly other 
species. 
The latent nature of the Pl cell-binding site was 
previously shown in radioligand assays with HT-1080 
cells [6]. We now examined the general nature of this 
masking effect by using a tryptic laminin fragment Tl 
which is larger than fragment Pl [12] and was an inac- 
tive adhesion substrate for the cell lines listed in table 
1. Progressive pepsin treatment of fragment Tl led to 
increased attachment activity reaching eventually the 
levels of authentic Pl (fig.2a). After exposure by pepsin 
treatment his RGD sequence becomes ensitive to tryp- 
sin, which reduces cell attachment activity to negligible 
levels (fig.2b). In agreement with this, trypsin treat- 
ment for 4 h reduced the inhibitory capacity of the 
cyclic 18-mer RGD-peptide of laminin (see above) to 
less than 5% (not shown). 
A structural explanation of these observations is pro- 
posed in fig.3, indicating that the EGF-like repeats pre- 
sent in the rod-like domains IIIa and IIIb in laminin A 
chain are connected to each other by a disulfide bond 
despite their separation in the primary sequence [9] by 
a 196-residue globular domain IVa, lacking cysteine 
residues. This would predict folding of IVa over adja- 
cent portions of IIIa/IIIb, making the RGD sequence 
in intact laminin and fragment Tl inaccessible to 
cellular receptors and trypsin. There are several facts 
supporting this prediction. The EGF-like repeats of 
IIIa/IIIb bordering the IVa sequence are both in- 
complete, but nevertheless complement each other to a 
full length repeat with 8 cysteine residues which should 
[25] bring domains IIIa and IIIb in close proximity 
(fig.3). Unmasking of the RGD could then occur by ex- 
tensive cleavage within domain IVa by pepsin without 
separating the link between domains IIIa and IIIb. This 
is supported by our sequence analysis of various small 
peptides obtained from pepsin digests of laminin- 
nidogen identifying two peptides with either 12 or 13 
residues which both share the N-terminal sequence 
IKGG starting at position 1243 in domain IVa (fig.3). 
It has been also observed that fragment Tl or similar 
adhesion-inactive fragments still possess globular do- 
mains of the short arms [22] which are no longer visible 
by electron microscopy after pepsin treatment 17,261. 
Yet, the rods in fragment Pl still have a length of 
84 
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Fig.2. Activation (a) and inactivation (b) of the cell-binding structure 
in laminin fragment Pl by protease treatment for the indicated 
periods of time. In (a) the tryptic laminin fragment Tl was treated 
with pepsin and in (b) the pepsin fragment PI was treated with tryp- 
sin. Cell-binding properties of starting materials (0 h) and of digested 
materials were then determined with A375 cells by constructing dose- 
response attachment profiles using a calorimetric assay 1181. Plateau 
levels of attachment are indicated by the bars. 
26-37 nm while a lo-12 nm long rod [9,25] would 
have to be observed if pepsin cleavage separates do- 
mains IIIa and IIIb. 
Recognition of RGD sequences in some adhesive 
proteins is due to cellular receptors of the integrin type 
[ 10,271. To examine this possibility for the Pl substrate 
we used an antiserum against human fibronectin recep- 
\ 
globular doman IVa 196 amino ocidreadues. no cyslane 
~LIKGGRARKWMD~ 
. . . 
Fig.3. Model of the possible disulfide bond junction between two in- 
complete EGF-like repeats in domains IIIa and IIIb of mouse laminin 
A chain to explain masking of the RGD cell-binding site by folding 
of the inserted domain IVa over adjacent regions in IIIa and IIIb. 
The model shows part of the amino acid sequence between positions 
1103-1416 of the A chain [9] with cysteine encircled. Numbering of 
the eight cysteines and disulfide bonding pattern (Cl-C3, C2-C4, 
CS-C6, C7-C8) is indicated as predicted [25] from the similarity to 
EGF. Borders of the predicted EGF-like repeat contributed by IIIa 
and IIIb are marked by arrows. A normal size of the loop in the 
postulated EGF-like repeat actually occupied by domain IVa is in- 
dicated by dots. The RGD sequence is boxed. Arrowheads in the do- 
main IVa sequence mark identified pepsin cleavage sites. 
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monoclonal antibody [)g/ml I 
antiserum dilution 
Fig.4. Inhibition of attachment of HTlOSO cells (full symbols) or 
A431 cells (open symbols) on a fragment Pl substrate by anti- 
receptor antibodies. Inhibitors were rabbit antiserum against human 
fibronectin receptor (O,O), a purified rat monoclonal antibody 
against the (~6 subunit of integrin VLA-6 (0) and for control normal 
rabbit serum (A). 
tor [21] which was previously shown to react with both 
its ,&l and a5 subunits. This antiserum showed com- 
plete and specific blocking of Pl adhesion of two cell 
lines (fig.4) which differ considerably in their sensitivity 
to inhibition by GRGDS peptide (table 1). A mono- 
clonal antibody (GoH3) specific for the cu6 subunit of 
integrins was previously found to inhibit platelet adhe- 
sion to laminin [20]. This antibody was incapable of 
preventing cell adhesion to laminin fragment Pl (fig.4) 
when tested in a concentration range completely block- 
ing cell adhesion of the same HT1080 cells to laminin 
or its major cell-binding fragment E8 [ 191. These data 
indicate that cell adhesion to fragment Pl is mediated 
by integrin receptors but since the 61 subunit is shared 
by several integrins [10,27] it does not suggest he ex- 
clusive involvement of the fibronectin receptor. 
Our data provide evidence that the single RGD se- 
quence present in the A chain component of laminin 
fragment Pl is involved in a latent cell-binding site with 
binding activity for integrin receptors. While apparent- 
ly recognized by a large variety of cells it may not repre- 
sent the only cell-binding site in Pl since the sequence 
YIGSR was also found to be active [23] and to prevent 
metastasis [28]. Mitogenic activity [29] and stimulation 
of pheochromocytoma PC12 cells (G. Tarone, personal 
communication) shared by laminin and its fragment P 1 
are insensitive to RGD and YIGSR peptide inhibition 
and therefore appear not to be masked indicating fur- 
ther independent cell-binding sites. The latent nature of 
the RGD binding site in fragment P 1 raises the question 
on its biological relevance, which would necessitate 
proteolytic activation in situ, for example, during base- 
ment membrane remodelling. Proteolysis is a common 
mechanism in interacting protein systems but usually 
does not involve proteases such as pepsin working at 
acidic pH. Recent data ([30,31] and our unpublished 
results) with endothelial cells interacting with laminin 
substrates at neutral pH show interference by RGD 
peptides suggesting that these cells may possess a func- 
tional activation mechanism. The elucidation of such 
mechanisms will be crucial in understanding the role of 
this cell adhesion reaction. 
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